Foreign Co-Authors & NIH Component Disclosure

NIH’s foreign-component disclosure rule is usually explained through funding relationships: a foreign subaward, a subcontract, a foreign collaborator drawing NIH dollars. But NIH has been explicit, most recently in a June 2026 NIH Extramural Nexus post, that a foreign component can arise from co-authorship and affiliation alone, with no money changing hands at all. Listing a foreign colleague as a co-author, or listing your own affiliation with a foreign institution on a publication, can itself be the fact pattern that triggers a disclosure obligation — independent of whether that collaborator was ever named on the award or paid from NIH funds.

This page covers that narrower, authorship-specific trigger. It assumes you already know the basics of what a foreign component is; if you need that grounding first, see CASRAI’s foreign component disclosure definition and the broader NIH foreign subaward requirements guide, which covers the funding-relationship side (PF5/UF5 subproject structure) that this page deliberately does not repeat.

What NIH means by a “foreign component”

NIH defines a foreign component as the performance of any significant scientific element or segment of a project outside the United States, whether or not NIH grant funds are expended to support it (NIH Grants Policy Statement, foreign component section; NOT-OD-21-073). The definition is deliberately broader than “foreign funding” — it reaches intellectual contribution, access to foreign facilities or data, and collaborative relationships with foreign investigators, not just subcontracted dollars.

The specific trigger: co-authorship and affiliations, not just funding

NIH’s June 2026 Extramural Nexus guidance, “Acknowledging Foreign Components throughout NIH Application and Award Processes,” addresses a pattern institutions kept getting wrong: treating foreign-component disclosure as purely a budget/subaward question, when a publication itself can be the evidence NIH points to.

Anticipated foreign co-authorship

Per that guidance, a collaboration with an investigator at a foreign site that is anticipated to result in co-authorship can constitute a foreign component — regardless of whether any NIH funds were expended to support that co-author’s involvement. In other words, the trigger isn’t “did we pay them,” it’s “did they meaningfully collaborate on NIH-supported work, and will that collaboration show up as a byline.” A co-authored manuscript resulting from that kind of substantive collaboration is treated as evidence the collaboration itself needed to be disclosed as a foreign component, even if it was never routed through a subaward or consultant agreement.

The minor-contribution exception

NIH’s own framing draws a real line here: not every foreign name on a byline is a foreign component. A contribution so minor that it doesn’t amount to an actual collaboration — NIH’s example is providing a single reagent — can still result in co-authorship under standard authorship-criteria practice (see CASRAI’s CRediT contributor roles overview for what “contribution” formally covers) without itself being a reportable foreign component. The distinction research administrators need to make is between an author credited for a discrete, minor input versus a genuine ongoing collaborative relationship with a foreign investigator or site that happens to culminate in co-authorship. That’s a judgment call best made by the PI and sponsored-programs office together, not an automatic rule triggered by any foreign affiliation appearing anywhere on a byline.

Affiliation accuracy on publications

The second half of the guidance is about affiliation listings, not co-author identity. NIH notes that affiliations shown in publications can themselves reveal an undisclosed foreign collaboration or component — and separately, that NIH-funded investigators should list the affiliation reflecting where the NIH-funded work was actually performed, not necessarily their current institutional affiliation if that differs from the performance site (for example, a PI who has since moved institutions, or who holds a secondary foreign appointment). An affiliation line that doesn’t match the disclosed performance site is exactly the kind of inconsistency that can prompt NIH to ask why a foreign site appears in a publication with no corresponding foreign-component disclosure on file.

Why this catches PIs and institutions off guard

Foreign-component compliance workflows are typically built around the proposal and award stages: current-and-pending support forms, Other Support disclosures, budget justifications, subaward agreements. Authorship happens downstream, at publication, often without sponsored-programs office involvement at all — a PI and their co-authors settle the author list and affiliations directly with the journal, sometimes months or years after the underlying award activity. If that collaboration was never disclosed as a foreign component because no formal subaward or budget line existed for it, the publication becomes the first, and sometimes only, place the relationship is documented anywhere — which is precisely why NIH is now calling attention to publications and progress reports as places where an undisclosed foreign component can surface.

When and how to disclose

Foreign components identified through anticipated or realized co-authorship should be disclosed the same way any other foreign component is: at initial application if known at that point, and afterward as a material change in scope reported to the awarding Institute or Center as soon as it’s identified — commonly through the Research Performance Progress Report (RPPR) or a prior-approval request, per standard NIH Grants Policy Statement change-of-scope procedures. Practical implications for research administration:

Ask PIs, at proposal stage and again at each progress report, whether any anticipated publications involve a foreign co-author or foreign-site collaboration — not just whether foreign funds or subawards exist.
Build a pre-submission or pre-publication check into manuscript workflows for NIH-funded projects, so a foreign co-authorship or foreign affiliation gets flagged to the sponsored-programs office before submission, not discovered after the fact during an audit or Other Support review.
Confirm that affiliation lines on manuscripts reflect where the funded work was actually performed, and reconcile any mismatch with what’s on file with NIH before submission.

How this differs from foreign subaward disclosure

CASRAI’s NIH foreign subaward requirements guide covers a formal funding relationship: a foreign organization performing a significant scientific element of the project under a subaward or, since NIH’s 2025 policy change, an independent foreign subproject (PF5/UF5 activity codes). That relationship exists because money and a documented scope of work moved to a foreign entity. The authorship trigger covered on this page can exist with no funding relationship at all — a foreign colleague can collaborate closely enough to earn co-authorship on an NIH-supported paper without ever being named in the budget, the Other Support disclosure, or a subaward agreement. Both are foreign components under the same NIH definition; they’re just detected through different evidence (a subaward document versus a byline or affiliation line), and an institution’s compliance workflow needs to catch both, not just the funded one.

How this differs from Other Support disclosure

CASRAI’s NIH Other Support template guide covers the biosketch/current-and-pending-support side: what a PI or senior/key personnel must disclose about all their research support and affiliations, foreign and domestic, at proposal and progress-report stages. Other Support disclosure is about the individual’s full portfolio of support and appointments. The authorship trigger on this page is about a specific project’s undisclosed collaborative relationship becoming visible through a specific publication. A foreign appointment that should have appeared on an Other Support form and a foreign co-authorship relationship that should have been disclosed as a component can be the same underlying fact discovered two different ways — which is part of why NIH increasingly cross-references publications against Other Support and progress-report disclosures rather than treating them as unrelated documents.

Frequently asked questions

Does a foreign co-author automatically mean I have an undisclosed foreign component?

No. NIH’s own guidance distinguishes a genuine collaborative relationship with a foreign investigator or site from a minor, discrete contribution (its example is providing a single reagent) that results in co-authorship without rising to the level of an actual collaboration. The test is the substance of the working relationship, not the mere presence of a foreign name or foreign affiliation on the byline.

Do I need to disclose a foreign co-author if no NIH funds were used to support their work?

Potentially yes. NIH’s foreign-component definition and its June 2026 guidance are explicit that a foreign component can exist regardless of whether NIH grant funds were expended on it — the trigger is the significant scientific collaboration, not the funding flow. Institutions should not assume “we didn’t pay them” resolves the disclosure question on its own.

Which affiliation should I list on a publication if I’ve since changed institutions?

NIH’s guidance directs investigators to list the affiliation reflecting where the NIH-funded work was actually performed, not necessarily a current affiliation if it differs from the performance site. A mismatch between the affiliation shown in print and the performance site on file with NIH is one of the specific patterns the June 2026 guidance flags as a way undisclosed foreign collaborations surface.

Who at my institution should review this before a manuscript is submitted?

Practice varies, but the sponsored-programs or research-security office typically owns foreign-component disclosure obligations, while the PI and co-authors control author list and affiliation decisions. Routing manuscripts with any foreign co-author or foreign-site involvement through a brief pre-submission compliance check closes the gap between those two groups before the paper — not an audit — becomes the first place NIH sees the relationship.

Related CASRAI resources

Sources

NIH, NIH Extramural Nexus, “Acknowledging Foreign Components throughout NIH Application and Award Processes” (June 2026), grants.nih.gov/news-events/nih-extramural-nexus-news
NIH Grants Policy Statement, foreign component definition and disclosure requirements
NOT-OD-21-073, NIH foreign component guidance